IQVIA Holdings Inc. $IQV Shares Sold by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 67,585 shares of the medical research company’s stock after selling 7,039 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in IQVIA were worth $11,915,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. American National Bank & Trust purchased a new stake in shares of IQVIA during the first quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC raised its position in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after buying an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA during the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. grew its stake in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.2%

Shares of IQV stock opened at $184.05 on Thursday. The company has a 50-day moving average of $178.75 and a two-hundred day moving average of $167.71. The firm has a market cap of $31.29 billion, a PE ratio of 26.64, a price-to-earnings-growth ratio of 2.09 and a beta of 1.32. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $250.46. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 9th. JPMorgan Chase & Co. dropped their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a report on Monday, May 19th. Truist Financial boosted their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Mizuho raised their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Finally, Redburn Partners set a $214.00 target price on shares of IQVIA in a report on Wednesday. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $229.86.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.